Pegylated-interferon-&#945;(2a) in clinical

practice: how to manage patients suffering from side effects by Calvaruso, V. et al.
1. Introduction
2. Hematologic side effects
3. Conclusion
4. Expert opinion
Review
Pegylated-interferon-a2a in clinical
practice: how to manage patients
suffering from side effects
Vincenza Calvaruso, Marta Mazza & Piero L Almasio†
†University of Palermo, Gastroenterology & Hepatology Unit, Dipartimento Biomedico di Medicina
Interna e Specialistica (Di.Bi.M.I.S.), Palermo, Italy
Introduction: The goal of antiviral therapy in patients with chronic hepatitis C
is to slow or halt the progression of fibrosis and prevent the development of
cirrhosis. Accordingly, antiviral treatment is proposed for a large population
of patients with chronic hepatitis.
Areas covered: The standard-of-care for chronic hepatitis C is the combination
of pegylated IFN (PEG-IFN) and ribavirin. The use of these drugs has been cor-
related with a range of adverse effects, including influenza-like symptoms,
hematological changes and neuropsychiatric disturbances. The effects of
these adverse events associated with PEG-IFN therapy are manifold and are
a major reason why patients decline or stop therapy. This review addresses
the screening for adverse event risk factors and guides the patient to success
with adherence strategies.
Expert opinion: Knowledge of the side effects correlated with PEG-IFN is very
relevant for clinicians because it can allow them to arrange the best methods
for treating these effects and avoid the discontinuation of antiviral treat-
ment. Moreover, the use of new antiviral drugs will considerably shorten
treatment periods reducing many of the above-described side effects and,
thus, increase adherence to scheduled therapy.
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1. Introduction
HCV infection is recognized as a global health problem, with an estimated
200 million people infected worldwide. The treatment for chronic HCV infection
has evolved over the last decade from standard IFN monotherapy to combination
therapy with standard IFN and ribavirin (RBV) and, more recently, pegylated
(PEG)-IFN-a2a or -a2b and RBV combination therapy [1,2].
The use of IFN-a with or without RBV is frequently associated with a number
of adverse effects, including influenza-like symptoms, hematological changes and
neuropsychiatric disturbances. This is also true for PEG-IFNs, with similar side
effects, dose reduction and discontinuation of treatment. Side effects are observed
in almost 80% of patients receiving PEG-IFN and RBV combination therapy for
chronic HCV infection. Care of patients with chronic hepatitis C depends on rec-
ognition of those at increased risk for side effects, anticipation (and prevention) of
side effects and appropriate management when they occur. Furthermore, the abil-
ity to achieve a sustained virologic response (SVR) at the end of therapy depends
in part on the degree of patient compliance with treatment. Dose reduction of
these agents (or their discontinuation) because of side effects can potentially
compromise the outcome, depending on when dose reduction has occurred.
This review summarizes the major side effects associated with PEG-IFN-a2a in
the treatment of chronic HCV infection, describing the best evidence derived
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from an extensive, though not exhaustive, search of the litera-
ture (updated to the end of 2010) on the management of
their occurrence.
2. Hematologic side effects
Hematologic adverse events are the most common labo-
ratory abnormalities that lead to dose modifications or
discontinuation [3-5]. Therapy with standard and PEG-IFNs is
associated with rapid suppression of hematopoiesis.
2.1 Anemia
Anemia is extremely common among patients taking
PEG--RBV combination therapy for chronic hepatitis C [3,6,7].
Although RBV-induced hemolysis is the major contributor to
treatment-associated anemia [8-10], the etiology of anemia is
multifactorial, and is also caused by IFN suppression of the
normal compensatory bone marrow response. IFN is a potent
suppressor of all components of the bone marrow and inhibits
erythropoiesis, as evidenced by an inadequate reticulocyte
response to anemia. IFN has also been associated with autoim-
mune hemolytic anemia [11]. As a consequence, in clinical prac-
tice special care needs to be taken in patients with a history of
cardiac disease.
No studies to evaluate the use of erythropoietin (EPO) in
HCV-treated patients with IFN alone have been done. The
only studies to evaluate combined treatment concluded
that approaches involving EPO or darbepoetin were cost-
effective [9,10]. However, the cost-effectiveness was sensitive
to the rates of SVR, while there was no definitive evidence
that the use of these growth factors can increase SVR. Never-
theless, significant improvement of quality of life was
observed by maintaining the HB above 12 g/dl. Side effects
associated with the use of EPO include headache and
flu-like symptoms. Pure red cell aplasia due to the
development of anti-EPO antibodies has also been reported.
One case has been reported of a patient taking EPO while
on PEG--RBV [9]. Red cell aplasia due to EPO is considered
to be very rare, with an estimated incidence of 0.02/10,000
patient-years of exposure.
2.2 Neutropenia
The incidence of neutropenia in patients treated with PEG-
IFN is greater than that seen in standard IFN regimens and
is a frequent indication for dose reduction [3-5]. Rapid decrease
in the neutrophil count may be seen within the first 2 weeks
of therapy and usually stabilizes over the next 4 -- 6 weeks as
steady-state concentrations of PEG-IFN are achieved. The
neutrophil count rapidly returns to baseline after therapy is
discontinued [5]. A recent study of 25 patients with hepatitis
C given a single high dose of standard IFN followed by regu-
lar injections of standard or PEG-IFN detailed the hemato-
logic effects of these drugs [11]. Leukocytes were the most
affected cell lineage, and PEG-IFN had a similar effect on
neutrophils and lymphocytes, with a median drop of 21 and
31%, respectively, after a single dose of IFN. During daily
administration of IFN, or weekly administration of PEG-
IFN, the decline in the neutrophil count was larger than the
drop in the lymphocyte count. PEG-IFN had a greater
effect on the neutrophil count compared with standard IFN,
consistent with observations in clinical trials [11].
The major concern with neutropenia is the potential risk of
increased infectious complications. An analysis of 119 patients
with hepatitis C who were treated with IFN and RBV showed
a 34% decrease in the neutrophil count, with the steepest
decline during the first 4 weeks of therapy [12]. Among
22 infections that occurred, the most common were sinusitis,
pharyngitis and urinary tract infection. One patient, a
72-year-old man with cirrhosis, required hospitalization for
cellulitis and lower-extremity edema. None of the patients
who developed infections had pre-existing neutropenia or a
neutrophil count of < 750 cells/mm3 at any point in treat-
ment [13]. Similar analyses of databases from the registration
trials of PEG-IFN also showed no significant association
between neutropenia and infectious complications [3-5].
Current package insert labeling for PEG-IFN recommends
dose reduction for neutrophil counts below 750 cells/mm3.
Patients with neutropenia should have blood counts moni-
tored weekly until a steady level of neutropenia is assured.
Several small studies using G-CSF as an adjunctive agent
have suggested that higher neutrophil counts can be main-
tained during IFN therapy [14-18]. Additional investigation is
required before these agents can be recommended for routine
use to treat neutropenia associated with PEG-IFN therapy, as
G-CSF is costly and has its own unique side effect profile.
2.3 Thrombocytopenia
Thrombocytopenia is common in patients with advanced
liver disease. The cause is multifactorial, and is due in part
to increased sequestration in the spleen and reduced
Article highlights.
. The use of IFN-a with or without ribavirin in hepatitis C
is frequently associated with a number of adverse
effects.
. The ability to achieve a sustained virologic response
depends in part on the degree of patient compliance
with treatment.
. Only a minority of patients need premature
discontinuation because of side effects.
. Hematologic abnormalities and depression are frequent
indications for dose reductions.
. Treatment periods could be shortened adding protease
inhibitors to standard-of-care therapy without significant
loss of response.
. The time reduction could reduce the incidence of side
effects, and thus will increase adherence to
scheduled therapy.
This box summarizes key points contained in the article.
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production of thrombopoietin (a cytokine that regulates
megakaryocyte maturation and platelet production) [19]. IFN
also reduces the platelet count. In patients treated with
PEG-a2a and RBV, dose reduction is necessary in 3 -- 4%
of those treated with PEG--RBV versus 1% in those treated
with standard IFN and RBV [3,6].
Severe thrombocytopenia is usually seen only in those with
established cirrhosis or in rare patients in whom IFN induces
autoimmune thrombocytopenia. Platelet counts increase in
patients who have achieved an SVR to therapy possibly because
of a reduction in splenomegaly, improvement in hepatic fibro-
sis and increased production of thrombopoietin [20,21]. Manu-
facturers have provided recommendations for dose reduction
in patients who develop thrombocytopenia. Other than dose
reduction, there are no approved therapies available to augment
the platelet count in those undergoing treatment with PEG and
RBV. The development and use of platelet-derived growth
factors may enhance tolerability, safety and efficacy of IFN
therapy in patients with HCV. Eltrombopag is a small-
molecule agonist of the physiological target of thrombopoietin,
and leads to increased activation and differentiation of mega-
karyocytes. In a study of patients with hepatitis C cirrhosis, it
caused a dose-dependent increase in platelet counts, thus,
allowing the initiation of antiviral therapy [22].
2.4 Flu-like symptoms
Flu-like symptoms (fatigue, headache, low-grade fever, muscle
aches and arthralgia) are the most common side effects in
patients treated with PEG-IFN [3-5]. Virtually all patients will
experience at least one of these influenza-like side effects with
the first few doses of IFN. Fortunately, these symptoms gener-
ally resolve or become less severe after the first month of
therapy. Acetaminophen or ibuprofen taken at the time of
injection may ameliorate the myalgias, arthralgias, headache
and fever. Other drugs can be used, such as COX-2 inhibitors,
but there are no data suggesting this class of medications is
superior to acetaminophen or ibuprofen in this group of
patients. Simple practices, such as adequate hydration, a light
to moderate exercise program, and altering dosing schedules
to coincide with scheduled days off from work or a lighter
work load, help minimize these side effects [5].
2.5 Neuropsychiatric side effects
With improved management of anemia and other side effects
associated with treatment, neuropsychiatric reactions have
come to account for a progressively larger share of the overall
burden associated with treatment. Indeed, neuropsychiatric
side effects are increasingly recognized as a primary cause of
both treatment failure and clinical decisions not to start treat-
ment in the first place. The reasons for the high rates of depres-
sion in HCV-infected individuals are unknown but may be
related to excessive fatigue or concerns about long-
term prognosis [23]. In addition, some patients with chronic hep-
atitis C have additional risk factors for depression, including
concurrent or past substance abuse. The proposed mechanisms
of IFN-induced depression, including changes in central adren-
ergic, serotonergic, opioid and neuroendocrine systems, have
been reviewed [23,24], but remain largely speculative. A number
of studies have pointed to the impact on serotonin pathways as
an explanation for the neuropsychiatric effects of IFN therapy.
IFN significantly increases serum kynurenine (a metabolite of
tryptophan) concentrations, and significantly reduces plasma
tryptophan and serum serotonin concentrations [25].
Increased serotonin turnover induced by IFN corresponds
to increases in the depression scores on the Montgomery--
Asberg Depression Rating Scale and the Hamilton Rating
Scale for Anxiety. Decreased levels of the serotonin metabo-
lite 5-hydroxyindolacetic acid are found in the cerebral spi-
nal fluid of IFN-treated subjects [26]. IFN-a-induced
depression has also been reported to be associated with
IL-6 and hypometabolism in the prefrontal cortex as mea-
sured by positron emission tomography [27,28]. Although sig-
nificant pre-existing psychiatric illness, particularly bipolar
disorder, has been considered a contraindication to IFN-
based medications, a recent study evaluated the effects of
IFN and RBV in high-risk groups that included patients
with psychiatric disorders, those on methadone mainte-
nance, those who were former drug addicts and controls
with hepatitis C, and found no contraindications [29].
Approximately 20 -- 30% of patients treated with PEG-
IFN and RBV will report depression during therapy, mak-
ing this a frequent cause of decreased quality of life, and
an indication for dose reduction or discontinuation. Under-
lying depression and anxiety are associated with decreased
compliance, which can compromise efficacy [30]. There is
growing consensus that selective serotonin reuptake inhibi-
tors (SSRIs) may be the class of choice for treating depres-
sion associated with IFN therapy in patients with chronic
hepatitis C [31]. SSRIs appear to be safe and well tole-
rated in patients with liver disease [32]. Conversely, the
prophylactic administration of antidepressant drugs offers
no advantages in the management of depression [33].
2.6 Respiratory tract symptoms
Respiratory tract symptoms, including a non-productive
cough and shortness of breath, are relatively common with
IFN monotherapy, and occur at a similar rate in those treated
with PEG--RBV (24 vs 26%) [3]. RBV use may be associated
with a persistent cough in the absence of any objective airway
disease. The etiology of dyspnea is usually related to the sever-
ity of anemia. However, interstitial lung disease, alveolar dis-
ease and sarcoidosis have been reported in hepatitis C therapy
treated with IFN [34-37]. In a series of five patients, bronchiol-
itis obliterans organizing pneumonia and interstitial pneumo-
nitis were reported in patients treated with PEG-IFN or
IFN-a2b [34,35]. Some of these patients presented with persis-
tent cough and underwent lung biopsy, showing bronchiolitis
obliterans organizing pneumonia or interstitial pneumonitis.
Thus, persistent dyspnea and persistent cough should be
investigated, and therapy may need to be discontinued.
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Interstitial pneumonitis associated with IFN can be severe
and life-threatening, though it is usually reversible on discon-
tinuation of IFN [38,39]. Reports of sarcoidosis with significant
dyspnea and dependency on steroids have been pub-
lished [36,37]. The presence of pulmonary or systemic sarcoid-
osis is generally considered a contraindication to therapy with
IFN-based medications.
2.7 Ophthalmologic disorders
Ophthalmologic disorders (retinal hemorrhages, cotton wool
spots, loss of color vision and, rarely, retinal artery or vein
obstruction) can occur during IFN therapy. The most com-
mon ocular complication is the development of a mild-to-
moderate ischemic retinopathy. On fundoscopy, the two
most common signs with IFN-related retinopathy are cotton
wool spots and retinal hemorrhages that resemble diabetic ret-
inopathy. They are usually found at the posterior pole around
the optic nerve head, and typically occur within 1 -- 3 months
of treatment, which makes it important to see patients for a
baseline examination at the beginning of IFN treatment. Cot-
ton wool spots and retinal hemorrhages normally resolve
spontaneously during or after treatment [40,41]. The incidence
of this retinopathy varies greatly in different reports (ranging
from 2 to 86%), though in most cases it was not associated
with significant visual loss. The risk may be greater in patients
with a history of hypertension or diabetes mellitus.
Several cases of glaucoma have also been reported in asso-
ciation with IFN therapy, but a causative association
remains unproven [42]. Case reports have also described a
toxic effect of IFN on the optic nerve, in which patients pre-
sented with blurred vision similar to that seen with optic
neuritis [43,44].
Patients should be cautioned about the possibility of visual
disturbance when they are treated with IFN therapy. We sug-
gest a baseline retinal examination performed by an ophthal-
mologist in patients who have diabetes or hypertension prior
to treatment, followed by a regular fundoscopic examination
during treatment. In addition, we refer patients for prompt
ophthalmologic examination for any new ophthalmologic
complaints, particularly changes in visual acuity.
2.8 Thyroid dysfunction
The development of thyroid dysfunction is common in
patients treated with IFN [45-50]. The most common IFN-a-
associated thyroid abnormality is the development of antithy-
roid antibodies with no clinical disease (5 -- 15% of patients).
Approximately 5 -- 10% of patients develop one of three auto-
immune thyroid diseases. Patients can develop hyperthyroid-
ism associated with Graves’ disease, painless thyroiditis (a
variant of Hashimoto’s thyroiditis) with a triphasic course of
transient hyperthyroidism followed by transient hypothyroid-
ism with a return to euthyroidism, or hypothyroidism associ-
ated with Hashimoto’s thyroiditis. More rarely, patients may
develop hypothyroidism that does not appear to be related
to underlying autoimmunity.
All patients receiving IFN-a should be monitored for thyroid
disease, particularly women and patients with pre-existing
antithyroid antibodies. We suggest measuring TSH and anti-
thyroid antibodies before treatment and every 12 weeks during
treatment. IFN therapy can usually be continued while
hypothyroidism is being treated. Asymptomatic biochemical
hyperthyroidism due to Graves’ disease or painless thyroiditis
that is picked up on scheduled thyroid testing can be observed
closely and, if symptoms are minimal, low dose propranolol
can be instituted. If clinically apparent hyperthyroidism devel-
ops, we stop PEG--RBV and get specialist endocrinology assis-
tance with further management. Following IFN withdrawal,
spontaneous normalization of thyroid function can be expected
in many, but not all, patients with hypothyroidism, though not
in those who develop Graves’ disease. Persistent antithyroglobu-
lin and antithyroid peroxidase antibodies after cessation of IFN
therapy predict the later development of thyroid dysfunction.
2.9 Autoimmune disease exacerbation
A variety of other autoimmune diseases can develop or be
exacerbated during IFN therapy, including psoriasis, vitiligo,
rheumatoid arthritis, lichen planus, dermatitis herpetiformis
and type 1 diabetes mellitus [51-55]. Thus, IFN should be
used with caution in patients with known autoimmune dis-
ease and is contraindicated in patients with known
autoimmune hepatitis.
2.10 Dermatologic complications
HCV has been associated with multiple dermatologic complica-
tions, including leukocytoclastic vasculitis, porphyria cutanea
tarda, lichen planus, erythema nodosum, urticaria, erythema
multiforme and polyarteritis nodosa [51-54]. Both IFN and
RBV have been associated with rashes. The most common is
a nonspecific, pruritic rash associated with flaky dry skin.
Although the rash has been attributed to RBV, it appears to
be more common in those treated with PEG--RBV combina-
tion therapy. The rash resolves over time in many patients,
but may require a reduction in the dose of RBV (or discontin-
uation) if it is severe. All patients are advised to avoid powerful
skin detergents and to use regular, non-perfumed skin moistur-
izers in addition to sunblock. In cases of persistent symptoms,
we also suggest a low-potency steroid cream (1% hydrocorti-
sone) and non-sedating antihistamine (loratadine 10 mg/day).
The administration of systemic steroids may be useful in
patients with severe pruritus in order to avoid discontinuation
of treatment in patients with virological response.
Erythema and induration are practically constant at the
IFN injection site, and may occasionally deteriorate to painful
nodules, though they rarely ulcerate. If severe injection site
reactions occur, we immediately assess injection technique
and avoid further injections in that region.
2.11 Hair loss
Reversible hair loss occurs in ~ 20% of patients, probably due
to telogen effluvium, as a result of IFN [56]. While it resolves
PEG-IFN-a2a in clinical practice: how to manage patients suffering from side effects
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on discontinuation of therapy, it can be distressing to patients.
Anecdotal experience suggests hair loss may be reduced by
using silk/satin pillow cases, avoiding high pressure showers
and cutting long hair. Topical minoxidil has also been used,
though its efficacy is unclear. Normal hair growth resumes
within 3 -- 6 months following discontinuation of treatment.
Irreversible alopecia associated with RBV and PEG-IFN ther-
apy [57] and autoimmune lopecia areata have also been
reported with IFN, but are rare [58].
2.12 Hearing loss
Though extremely rare, sudden hearing loss and tinnitus have
been described with IFN and PEG-IFN plus RBV combina-
tion therapy [59]. The mechanism is unclear but may be
related to direct ototoxicity of IFN, autoimmunity or hemato-
logic changes. Hearing loss does not fully resolve in all
patients after discontinuing therapy. On the other hand,
continuation of therapy may not worsen symptoms.
3. Conclusion
Most of the patients treated with PEG-IFN experience some
adverse events during therapy. However, most adverse events
can be managed properly so that only a minority of patients
will require premature discontinuation because of side effects.
Hematologic abnormalities and depression are frequent indi-
cations for dose reductions. The use of hematopoietic growth
factors may improve the quality of life and the management
of adverse events during IFN-based antiviral therapy. Further
studies are required on the mechanisms of IFN-induced
depression, which will facilitate the development of new
therapeutic approaches.
At present, several direct-acting antiviral drugs are under
clinical assessment. Recent clinical trials evaluating the
most advanced compounds, telaprevir and boceprevir, indi-
cate that the addition of these protease inhibitors to stan-
dard-of-care therapy considerably increases the rate of SVR
in treatment-naive patients, as well as in relapsers, and
nonresponders to standard therapy [60,61]. The clear evidence
that overall treatment periods can be shortened considerably
with no significant loss of response could reduce many of the
above-described side effects of PEG-IFN, and thus increase
adherence to scheduled therapy.
4. Expert opinion
The relevant clinical benefits of IFN-based treatment
encourage clinicians to propose the therapy to a majority
of patients with chronic hepatitis C. The side effects of the
standard-of-care therapy discussed in this paper could affect
a large number of patients, but mounting knowledge of
these complications and increased physician experience
may allow for correct management and avoidance of
treatment discontinuation in the majority of cases.
Growth factor therapy, used mostly for anemia and neu-
tropenia, has an important role in the management of
hematologic adverse events during antiviral treatment.
A prospective study performed in a large cohort of patients
would be useful in assessing their impact on patient compli-
ance and, consequently, on the rate of SVR. Furthermore, a
definitive collection of guidelines for the correct manage-
ment of the different kinds of side effects should be
undertaken and studied in order to improve the treatment
of these patients and diminish dose reductions or
treatment discontinuation.
Future treatment with protease inhibitors will change the
current approach to the treatment of HCV infection. New
therapeutic protocols would ideally include a combination
of PEG-IFN, RBV and protease and/or polymerase inhibi-
tors, and so it is possible that patients will experience side
effects that are different from those previously reported. How-
ever, combined therapy can result in a shortened treatment
period, and this should improve patient compliance.
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